Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHRA reclassifies two products to general sale

This article was originally published in Scrip

Executive Summary

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has reclassified two products from pharmacy to general sales list: nicotine nasal spray, 0.5mg nicotine per spray, as a smoking cessation aid in adults and children over 12 years of age, and benzocaine throat spray, 1mg per spray, for the relief of sore throat pain in adults and children over six.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts